DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Esophageal Cancer - Pipeline Review, H2 2016" report to their offering.
Esophageal Cancer pipeline therapeutics constitutes close to 76 molecules. Out of which approximately 69 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Esophageal Cancer - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Esophageal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Esophageal Cancer Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Risk factors include age, smoking, obesity and bile reflux. Treatment includes chemotherapy, radiation therapy and surgery.
The molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 34, 19, 1, 8 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 2 and 1 molecules, respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects.
Key Topics Covered:
- Introduction
- Esophageal Cancer Overview
- Therapeutics Development
- Pipeline Products for Esophageal Cancer - Overview
- Pipeline Products for Esophageal Cancer - Comparative Analysis
- Esophageal Cancer - Therapeutics under Development by Companies
- Esophageal Cancer - Therapeutics under Investigation by Universities/Institutes
- Esophageal Cancer Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Esophageal Cancer - Products under Development by Companies
- Esophageal Cancer - Products under Investigation by Universities/Institutes
- Esophageal Cancer - Companies Involved in Therapeutics Development
- Adaptimmune Therapeutics Plc
- Amgen Inc.
- Array BioPharma Inc.
- Aslan Pharmaceuticals Pte. Ltd.
- ATLAB Pharma SAS
- Bayer AG
- Betta Pharmaceuticals Co. Ltd.
- Boehringer Ingelheim GmbH
- Celgene Corporation
- Cerulean Pharma, Inc.
- Cyclacel Pharmaceuticals, Inc.
- F. Hoffmann-La Roche Ltd.
- Genmab A/S
- GlaxoSmithKline Plc
- Ignyta, Inc.
- ImmunoFrontier, Inc.
- Immunomedics, Inc.
- Johnson & Johnson
- Komipharm International Co., Ltd.
- MacroGenics, Inc.
- MaxiVAX SA
- Merck & Co., Inc.
- Mirna Therapeutics, Inc.
- Novartis AG
- Omeros Corporation
- Omnitura Therapeutics Inc.
- Oncolys BioPharma Inc
- OncoMed Pharmaceuticals, Inc.
- Ono Pharmaceutical Co., Ltd.
- Pfizer Inc.
- Proteo, Inc.
- Puma Biotechnology, Inc.
- Rhizen Pharmaceuticals S.A.
- Shionogi & Co., Ltd.
- XuanZhu Pharma Co., Ltd.
For more information about this report visit http://www.researchandmarkets.com/research/c2qnv2/esophageal_cancer
